DBV Technologies S.A. (DBVT) company profile
Close on Nov 16, 2026Market cap $645.75MP/E –Yield –
About DBV Technologies
Biological Products, (No Diagnostic Substances), SIC 2836
DBV Technologies is a clinical-stage biopharmaceutical company that develops epicutaneous immunotherapy treatments using a skin patch platform called Viaskin. The technology delivers microgram amounts of antigens through intact skin to activate immune cells without entering the bloodstream. The company's primary candidate is the Viaskin Peanut patch, which is evaluated for treating peanut allergies in toddlers and children. Additionally, the firm develops earlier-stage product candidates, including Viaskin Milk for cow's milk allergy and eosinophilic esophagitis. Its intended end users are pediatric patients suffering from severe food allergies, supported by parents, caregivers, allergists, and pediatricians.
The company conducts clinical research globally, evaluating hundreds of pediatric participants across multiple Phase 2 and Phase 3 clinical trials. Its clinical development and regulatory pursuits focus on the United States and the European Union. The text also references patient survey data gathered across eight European countries. The provided text does not disclose the company's headquarters.
Summary of the business section of DBV Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- DBV Technologies S.A.
- Founded
- 2002
- Headquarters
- Chatillon, France
- Address
- 107 Avenue De La Republique
- Phone
- 330155427878
- Website
- www.dbv-technologies.com
- Employees
- 125, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- I0
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Associes, Paris-La Defense
Stock & identifiers
- Ticker
- DBVT
- Other tickers
- DBVTF
- Exchange
- Nasdaq
- IPO date
- Oct 22, 2014
- Shares outstanding
- 314M, Oct 26, 2026
- Public float
- $250.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-2 reverse, Jun 7, 2024
- SEC CIK
- 1613780
- CUSIP
- 23306J309
- ISIN
- US23306J3095
- FIGI
- BBG0076D3T39
- Share class FIGI
- BBG0076D3TV8
- LEI
- 969500PVBQFWQKVDMD80
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel Tasse | CHIEF EXECUTIVE OFFICER, Director | 17,094 |
| Pharis Mohideen | Chief Medical Officer | 144,531 |
| Virginie Boucinha | Chief Financial Officer | 70,000 |
| Kevin Michael Trapp | Chief Commercial Officer | 55,000 |
| Philina Lee | Director | – |
| Brothers Life Sciences LP Baker | Director | 1,200,369 |
| Bros. Advisors (GP) LLC Baker | Director | 1,585,054 |
| 667, L.P. | Director | – |
| Felix Baker | Director | – |
| Julian Baker | Director | – |
| Bros. Advisors Lp Baker | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.36M | $7.66M | $1.36M | $125 | – |
| FY2024 | $1.62M | -$506.08K | $639.61K | $20 | – |
| FY2023 | $2.44M | $978.12K | $631.15K | $62 | – |
| FY2022 | $2.79M | $2.95M | $789.22K | $96 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Daniel Tassé Chief Executive Officer and Director | $600.00K | $780.00K | $1.92M | $62.57K | $3.36M | +107% |
| Virginie Boucinha Chief Financial Officer | $350.45K | $249.70K | $86.42K | $381.49K | $1.07M | +133% |
| Pharis Mohideen Chief Medical Officer | $590.79K | $430.22K | $118.82K | $502.69K | $1.64M | +100% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 22, 2014
- Offer price
- $43.27
- Securities offered
- 4,277,826
- Gross proceeds
- $185.10M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Apr 20, 2015
“Per Share Per ADS Total(1) Public Offering Price $ 43.27 $ 21.64 $ 92,572,155 Underwriting Discount(2) $ 3.0289 $ 1.5148 $ 6,480,051 Proceeds to DBV (before expenses) $ 40.2411 $ 20.1252 $ 86,092,104 (1) Total gross proceeds from the global offering, including the French registered private placement, are $115,693,259.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 31, 2025 | Late filing | Notification of late filing |
| Dec 16, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 18, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 22, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 30, 2021 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 21, 2021 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 22, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 17, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?